RenovoRx, Inc. (RNXT)
NASDAQ: RNXT · Real-Time Price · USD
0.8600
-0.0256 (-2.89%)
Jun 9, 2026, 4:00 PM EDT - Market closed
RenovoRx Revenue
RenovoRx had revenue of $563.00K in the quarter ending March 31, 2026, with 185.79% growth. This brings the company's revenue in the last twelve months to $1.49M, up 520.42% year-over-year. In the year 2025, RenovoRx had annual revenue of $1.12M with 2,511.63% growth.
Revenue (ttm)
$1.49M
Revenue Growth
+520.42%
P/S Ratio
26.05
Revenue / Employee
$87,588
Employees
17
Market Cap
38.79M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.12M | 1.08M | 2,511.63% |
| Dec 31, 2024 | 43.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRNXT News
- 5 days ago - RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd - GlobeNewsWire
- 12 days ago - RenovoRx announces FDA Orphan Drug Designation for oxaliplatin - TheFly
- 12 days ago - RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer - GlobeNewsWire
- 14 days ago - RenovoRx announces pharmacokinetic data using TAMP platform - TheFly
- 14 days ago - RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting - GlobeNewsWire
- 20 days ago - RenovoRx Transcript: A.G.P.'s Annual Virtual Healthcare Conference - Transcripts
- 21 days ago - RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th - GlobeNewsWire
- 26 days ago - RenovoRx reports Q1 adjusted EPS (8c), consensus (8c) - TheFly